Novo Nordisk Shares Drop After CagriSema Trial Data Falls Short of Expectations
CagriSema produced an average 15.7% weight reduction in overweight or obese individuals with type 2 diabetes, according to the research results. Weight reduction under the trial product estimand (if all adhered to treatment) was 15.
Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline ...
A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...
Danish diabetes and obesity giant Novo Nordisk (NOV: N) today announced headline results from REDEFINE 2, a Phase III trial ...
Novo Nordisk (NVO) announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE program. REDEFINE 2 is a 68-week efficacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback